ONE PILL,
ONCE DAILY1
RINVOQ Dosing
One Easy-to-Open Bottle
Awarded the Arthritis Foundation Ease of Use Commendation,2 our innovative bottle cap includes:
- Wide, easy-to-grip texture
- Embedded tool that seamlessly punctures the foil liner to simplify medication access
A Once-Daily Oral Therapy1
Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
- RINVOQ is a 15 mg extended-release pill
- Take one pill 1 time a day with or without food
- Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ
- Swallow pill whole. Do not split, crush, or chew
- Instruct patients to notify their healthcare provider if they repeatedly notice intact RINVOQ tablet or fragments in stool or ostomy output
- Store at 36˚F to 77˚F (2˚C to 25˚C) in the original bottle in order to protect from moisture
- In clinical trials, RINVOQ mean terminal elimination half-life ranged from 8-14 hours
Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.
Lab Monitoring & Dosing Considerations
Lab Monitoring and Dosing Considerations1
<<Swipe table to see more
| Evaluate at baseline | Evaluate according to routine patient management | 12 weeks after initiation and thereafter according to clinical guidelines | ||||
|---|---|---|---|---|---|---|
| Neutrophils |  |
|
||||
| Lymphocytes | |
|
||||
| Hemoglobin | |
|
||||
| Lipidsa | |
|||||
| Liver enzymes | |
|
TREATMENT WITH RINVOQ SHOULD NOT BE INITIATED, OR SHOULD BE INTERRUPTED IF:
Absolute neutrophil count
<1000 cells/mm3*
Absolute lymphocyte
count <500 cells/mm3*
Hemoglobin levels
<8 g/dL*
Liver enzyme elevations
and a drug-induced liver
injury is suspected*
Patient has or develops
a serious or
opportunistic infection*
*Treatment can be initiated or restarted after levels return above specified values, drug-induced liver injury diagnosis is excluded, or infection is controlled.
In RA, PsA, AS, and nr‑axSpA:
No dose adjustment is required for mild, moderate, or severe renal impairment.1
No dose adjustment is required for mild or moderate hepatic impairment.1
RINVOQ is not recommended in patients with1:
- Active hepatitis B or hepatitis C
- Severe hepatic impairment (Child‑Pugh C)
RINVOQ has not been studied in end‑stage renal disease (eGFR <15 mL/min/1.73 m2).1
HYPERSENSITIVITY1: RINVOQ is contraindicated in patients with known hypersensitivity to upadacitinib or any of its excipients. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.
Lab Abnormalities from the Package Insert1
Neutropenia: Decreases in absolute neutrophil count (<1000 cells/mm3) were associated with RINVOQ treatment.
Lymphopenia: Decreases in lymphocyte count (<500 cells/mm3) were reported with RINVOQ treatment.
Anemia: Hemoglobin decreases below 8 g/dL were reported with RINVOQ treatment.
Lipid Elevations: Increases in lipid parameters, including total cholesterol, triglycerides, LDL, and HDL, were observed in patients treated with RINVOQ. Elevations in LDL and HDL cholesterol peaked by Week 8 and remained stable thereafter.
Liver Enzyme Elevations: Increased incidences in liver enzyme elevations were associated with RINVOQ compared to placebo.